BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodés J. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30:890-895. [PMID: 10365817 DOI: 10.1016/s0168-8278(99)80144-5] [Cited by in Crossref: 364] [Cited by in F6Publishing: 111] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012; 3(4): 49-61 [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
3 Feuerstadt P, Hong SJ, Brandt LJ. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection. Dig Dis Sci 2020;65:632-8. [DOI: 10.1007/s10620-019-05804-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Germanese D, Colantonio S, D'Acunto M, Romagnoli V, Salvati A, Brunetto M. An E-Nose for the Monitoring of Severe Liver Impairment: A Preliminary Study. Sensors (Basel) 2019;19:E3656. [PMID: 31443499 DOI: 10.3390/s19173656] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lunia MK, Sharma BC, Sachdeva S. Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. Hepatol Int. 2013;7:268-273. [PMID: 26201641 DOI: 10.1007/s12072-012-9360-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
6 Saleh ZM, Solano QP, Louissaint J, Jepsen P, Tapper EB. The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis. United European Gastroenterol J 2021;9:672-80. [PMID: 34102040 DOI: 10.1002/ueg2.12104] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Singh SP, Wadhawan M, Acharya SK, Bopanna S, Madan K, Sahoo MK, Bhat N, Misra SP, Duseja A, Mukund A, Anand AC, Goel A, Satyaprakash BS, Varghese J, Panigrahi MK, Tandan M, Mohapatra MK, Puri P, Rathi PM, Wadhwa RP, Taneja S, Thomas V, Bhatia V; Indian Society of Gastroenterology Task Force on Upper Gastrointestinal Bleeding. Management of portal hypertensive upper gastrointestinal bleeding: Report of the Coorg Consensus workshop of the Indian Society of Gastroenterology Task Force on Upper Gastrointestinal Bleeding. Indian J Gastroenterol 2021. [PMID: 34890020 DOI: 10.1007/s12664-021-01169-5] [Reference Citation Analysis]
8 Wu H, Li N, Jin R, Meng Q, Chen P, Zhao G, Wang R, Li L, Li W. Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation. Sci Rep 2016;6:18528. [PMID: 26757951 DOI: 10.1038/srep18528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
9 Hudson M, Radwan A, Di Maggio P, Cipelli R, Ryder SD, Dillon JF, Cash WJ, Przemioslo RT, Wright M, Shawcross DL, Jalan R, Saksena S, Allison M, Richardson P, Farrington E, Aspinall RJ. The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Frontline Gastroenterol 2017;8:243-51. [PMID: 29067149 DOI: 10.1136/flgastro-2016-100792] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
10 Liu C, Wang L, Xu M, Sun Y, Xing Z, Zhang J, Wang C, Dong L. Reprogramming the spleen into a functioning 'liver' in vivo. Gut 2022:gutjnl-2021-325018. [PMID: 34996824 DOI: 10.1136/gutjnl-2021-325018] [Reference Citation Analysis]
11 Waghray N, Waghray A, Mullen K. Treatment options for covert hepatic encephalopathy. Curr Treat Options Gastroenterol. 2014;12:229-241. [PMID: 24623592 DOI: 10.1007/s11938-014-0014-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Legaz I, Bolarin JM, Campillo JA, Moya RM, Luna A, Osuna E, Minguela A, Sanchez-Bueno F, Alvarez MR, Muro M. Pretransplant ascites and encephalopathy and their influence on survival and liver graft rejection in alcoholic cirrhosis disease. Arch Med Sci 2021;17:682-93. [PMID: 34025838 DOI: 10.5114/aoms.2018.80651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Tanaka T, Sugawara Y, Kokudo N. Liver transplantation and autoimmune hepatitis. Intractable Rare Dis Res 2015;4:33-8. [PMID: 25674386 DOI: 10.5582/irdr.2014.01034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
14 Colmenero J, Castro-Narro G, Navasa M. [The value of MELD in the allocation of priority for liver transplantation candidates]. Gastroenterol Hepatol 2010;33:330-6. [PMID: 19631411 DOI: 10.1016/j.gastrohep.2009.04.007] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
15 Nath A, Haktanirlar G, Varga Á, Molnár MA, Albert K, Galambos I, Koris A, Vatai G. Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System. Medicina (Kaunas) 2018;54:E18. [PMID: 30344249 DOI: 10.3390/medicina54020018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Amodio P, Montagnese S. Lights and Shadows in Hepatic Encephalopathy Diagnosis. J Clin Med 2021;10:341. [PMID: 33477554 DOI: 10.3390/jcm10020341] [Reference Citation Analysis]
17 Hashimoto N, Akahoshi T, Shoji T, Tomikawa M, Tsutsumi N, Yoshizumi T, Taketomi A, Shirabe K, Maehara Y. Successful treatment for hepatic encephalopathy aggravated by portal vein thrombosis with balloon-occluded retrograde transvenous obliteration. Case Rep Gastroenterol 2011;5:366-71. [PMID: 21769289 DOI: 10.1159/000330287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Jeong JY, Jun DW, Bai D, Kim JY, Sohn JH, Ahn SB, Kim SG, Kim TY, Kim HS, Jeong SW, Cho YK, Song DS, Kim HY, Jung YK, Yoon EL. Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea. J Korean Med Sci. 2017;32:1484-1490. [PMID: 28776344 DOI: 10.3346/jkms.2017.32.9.1484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Chavarria L, Cordoba J. Encephalopathy and liver transplantation. Metab Brain Dis 2013;28:285-92. [PMID: 23154925 DOI: 10.1007/s11011-012-9350-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
20 Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017;5:142-151. [PMID: 28660152 DOI: 10.14218/jcth.2016.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
21 Teh KB, Loo JH, Tam YC, Wong YJ. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis. Dig Liver Dis 2021;53:817-23. [PMID: 34011479 DOI: 10.1016/j.dld.2021.04.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: From diagnosis to therapeutic strategies. Ann Gastroenterol. 2018;31:151-164. [PMID: 29507462 DOI: 10.20524/aog.2018.0232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
23 Londoño MC, Cárdenas A, Guevara M, Quintó L, de Las Heras D, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Ginès P. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283-1290. [PMID: 17452425 DOI: 10.1136/gut.2006.102764] [Cited by in Crossref: 136] [Cited by in F6Publishing: 117] [Article Influence: 9.1] [Reference Citation Analysis]
24 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
25 Montoliu C, Piedrafita B, Serra MA, del Olmo JA, Ferrandez A, Rodrigo JM, Felipo V. Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients. J Mol Med (Berl). 2007;85:237-245. [PMID: 17216205 DOI: 10.1007/s00109-006-0149-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
26 Claeys W, Van Hoecke L, Lefere S, Geerts A, Verhelst X, Van Vlierberghe H, Degroote H, Devisscher L, Vandenbroucke RE, Van Steenkiste C. The neurogliovascular unit in hepatic encephalopathy. JHEP Rep 2021;3:100352. [PMID: 34611619 DOI: 10.1016/j.jhepr.2021.100352] [Reference Citation Analysis]
27 Stinton LM, Jayakumar S. Minimal hepatic encephalopathy. Can J Gastroenterol 2013;27:572-4. [PMID: 24106728 DOI: 10.1155/2013/547670] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
28 Ampuero J, Ranchal I, del Mar Díaz-Herrero M, del Campo JA, Bautista JD, Romero-Gómez M. Role of diabetes mellitus on hepatic encephalopathy. Metab Brain Dis 2013;28:277-9. [PMID: 23180316 DOI: 10.1007/s11011-012-9354-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
29 Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev 2019;6:CD012334. [PMID: 31204790 DOI: 10.1002/14651858.CD012334.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
30 Formentin C, Zarantonello L, Mangini C, Frigo AC, Montagnese S, Merkel C. Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE). Liver Int 2021;41:1070-82. [PMID: 33411388 DOI: 10.1111/liv.14785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Roggeri DP, Roggeri A. Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy. Hepat Med 2017;9:37-43. [PMID: 29026340 DOI: 10.2147/HMER.S146438] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
32 Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med. 2015;7:37-42. [PMID: 26203290 DOI: 10.2147/hmer.s87594] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
33 Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012;2012:480309. [PMID: 23133760 DOI: 10.1155/2012/480309] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
34 Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51:1397-405. [PMID: 32363684 DOI: 10.1111/apt.15749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
35 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;CD003044. [PMID: 27153247 DOI: 10.1002/14651858.cd003044.pub4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
36 Hassanein TI, Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci. 2008;53:529-538. [PMID: 17710551 DOI: 10.1007/s10620-007-9895-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
37 Li W, Li N, Wang R, Li Q, Wu H. Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients. Hepatol Int. 2015;9:218-223. [PMID: 25794550 DOI: 10.1007/s12072-015-9610-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
38 Kornerup LS, Pflugrad H, Weissenborn K, Vilstrup H, Dam G. Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy? Hepat Med 2019;11:41-6. [PMID: 31040728 DOI: 10.2147/HMER.S144667] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:236963. [PMID: 23653636 DOI: 10.1155/2013/236963] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
40 Grover VP, Crossey MM, Fitzpatrick JA, Saxby BK, Shaw R, Waldman AD, Morgan MY, Taylor-Robinson SD. Quantitative magnetic resonance imaging in patients with cirrhosis: a cross-sectional study. Metab Brain Dis 2016;31:1315-25. [PMID: 26251205 DOI: 10.1007/s11011-015-9716-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Bloom A, Mudiyansalage VW, Rhodes A, Hogg M, Jayasekera C, Gorelik A, Sood S, Nicoll A. Can adequate analgesia be achieved in patients with cirrhosis without precipitating hepatic encephalopathy? A prospective study. Clin Exp Hepatol 2020;6:243-52. [PMID: 33145431 DOI: 10.5114/ceh.2020.99521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jiang X, Xu L, Tang L, Liu F, Chen Z, Zhang J, Chen L, Pang C, Yu X. Role of the indoleamine-2,3-dioxygenase/kynurenine pathway of tryptophan metabolism in behavioral alterations in a hepatic encephalopathy rat model. J Neuroinflammation 2018;15:3. [PMID: 29301550 DOI: 10.1186/s12974-017-1037-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
43 Atla PR, Sheikh MY, Gill F, Kundu R, Choudhury J. Predictors of hospital re-admissions among Hispanics with hepatitis C-related cirrhosis. Ann Gastroenterol 2016;29:515-20. [PMID: 27708520 DOI: 10.20524/aog.2016.0072] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
44 Dhiman RK. Gut microbiota and hepatic encephalopathy. Metab Brain Dis. 2013;28:321-326. [PMID: 23463489 DOI: 10.1007/s11011-013-9388-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
45 Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, Luketic V, Stravitz RT, Fuchs M, Thacker LR, Gilles H, White MB, Unser A, Hovermale J, Gavis E, Noble NA, Wade JB. Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2015;13:1828-1835.e1. [PMID: 24846278 DOI: 10.1016/j.cgh.2014.05.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
46 Koziarska D, Wunsch E, Milkiewicz M, Wójcicki M, Nowacki P, Milkiewicz P. Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study. BMC Gastroenterol 2013;13:107. [PMID: 23815160 DOI: 10.1186/1471-230X-13-107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
47 Sijens PE, Alkefaji H, Lunsing RJ, van Spronsen FJ, Meiners LC, Oudkerk M, Verkade HJ. Quantitative multivoxel 1H MR spectroscopy of the brain in children with acute liver failure. Eur Radiol 2008;18:2601-9. [PMID: 18493780 DOI: 10.1007/s00330-008-1049-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ridola L, Riggio O, Gioia S, Faccioli J, Nardelli S. Clinical management of type C hepatic encephalopathy. United European Gastroenterol J 2020;8:536-43. [PMID: 32213035 DOI: 10.1177/2050640620909675] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
49 Mani AR, Montagnese S, Jackson CD, Jenkins CW, Head IM, Stephens RC, Moore KP, Morgan MY. Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2009;296:G330-G338. [PMID: 19023029 DOI: 10.1152/ajpgi.90488.2008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
50 Chautant F, Guillaume M, Robic MA, Cadranel JF, Peron JM, Lison H, Cool C, Bureau C, Duhalde V. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World J Hepatol 2020; 12(1): 10-20 [PMID: 31984117 DOI: 10.4254/wjh.v12.i1.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410. [PMID: 29762873 DOI: 10.1002/14651858.cd012410.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
52 Toshikuni N, Arisawa T, Tsutsumi M. Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol 2014; 20(23): 7286-7297 [PMID: 24966599 DOI: 10.3748/wjg.v20.i23.7286] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
53 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;8:CD002798. [PMID: 28796283 DOI: 10.1002/14651858.CD002798.pub4] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
54 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;7:CD002798. [PMID: 28745801 DOI: 10.1002/14651858.CD002798.pub3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Parés A, Deulofeu R, Cisneros L, Escorsell A, Salmerón JM, Caballería J, Mas A. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care. 2009;13:R8. [PMID: 19175915 DOI: 10.1186/cc7697] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
56 Córdoba J, García-Martinez R, Simón-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis. 2010;25:73-80. [PMID: 20217202 DOI: 10.1007/s11011-010-9172-3] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
57 Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, Stravitz RT, Luketic V, Fuchs M, White MB, Bell DE, Gilles H, Morton K, Noble N, Puri P, Sanyal AJ. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106:1646-1653. [PMID: 21556040 DOI: 10.1038/ajg.2011.157] [Cited by in Crossref: 201] [Cited by in F6Publishing: 173] [Article Influence: 18.3] [Reference Citation Analysis]
58 Chen HJ, Zhang L, Jiang LF, Chen QF, Li J, Shi HB. Identifying minimal hepatic encephalopathy in cirrhotic patients by measuring spontaneous brain activity.Metab Brain Dis. 2016;31:761-769. [PMID: 26886109 DOI: 10.1007/s11011-016-9799-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
59 Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag. 2009;5:617-626. [PMID: 19707277 DOI: 10.2147/tcrm.s4443] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
60 Northup PG, Abecassis MM, Englesbe MJ, Emond JC, Lee VD, Stukenborg GJ, Tong L, Berg CL; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl 2009;15:148-62. [PMID: 19177435 DOI: 10.1002/lt.21671] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
61 Romeiro FG, Augusti L. Nutritional assessment in cirrhotic patients with hepatic encephalopathy. World J Hepatol 2015; 7(30): 2940-2954 [PMID: 26730273 DOI: 10.4254/wjh.v7.i30.2940] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
62 Hirode G, Vittinghoff E, Wong RJ. Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. Dig Dis Sci 2019;64:1448-57. [PMID: 30863953 DOI: 10.1007/s10620-019-05576-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
63 Salehi S, Tranah TH, Lim S, Heaton N, Heneghan M, Aluvihare V, Patel VC, Shawcross DL. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther 2019;50:435-41. [PMID: 31169941 DOI: 10.1111/apt.15326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
64 Wang WW, Zhang Y, Huang XB, You N, Zheng L, Li J. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction. World J Gastroenterol 2017; 23(38): 6983-6994 [PMID: 29097871 DOI: 10.3748/wjg.v23.i38.6983] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
65 Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol 2020; 26(18): 2221-2231 [PMID: 32476788 DOI: 10.3748/wjg.v26.i18.2221] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
66 Jaeger V, DeMorrow S, McMillin M. The Direct Contribution of Astrocytes and Microglia to the Pathogenesis of Hepatic Encephalopathy. J Clin Transl Hepatol. 2019;7:352-361. [PMID: 31915605 DOI: 10.14218/jcth.2019.00025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
67 Ghoshal UC, Das A. Models for prediction of mortality from cirrhosis with special reference to artificial neural network: a critical review. Hepatol Int 2008;2:31-8. [PMID: 19669277 DOI: 10.1007/s12072-007-9026-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
68 Ampuero J, Ranchal I, Nuñez D, Díaz-Herrero Mdel M, Maraver M, del Campo JA, Rojas Á, Camacho I, Figueruela B, Bautista JD, Romero-Gómez M. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One 2012;7:e49279. [PMID: 23166628 DOI: 10.1371/journal.pone.0049279] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
69 Zhang M, Duan ZJ. Retrospective analysis of factors influencing the development and progression of hepatic encephalopathy in patients with hepatitis B virus-related cirrhosis. Shijie Huaren Xiaohua Zazhi 2012; 20(13): 1148-1155 [DOI: 10.11569/wcjd.v20.i13.1148] [Reference Citation Analysis]
70 Romeiro FG, Ietsugu MDV, Franzoni LC, Augusti L, Alvarez M, Santos LAA, Lima TB, Koga KH, Moriguchi SM, Caramori CA, Silva GF, Betting LEGG. Which of the branched-chain amino acids increases cerebral blood flow in hepatic encephalopathy? A double-blind randomized trial. Neuroimage Clin 2018;19:302-10. [PMID: 30013913 DOI: 10.1016/j.nicl.2018.03.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Allampati S, Duarte-Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, John B, Heuman DM, Wade JB, Flud C, O'Shea R, Gavis EA, Unser AB, Bajaj JS. Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study. Am J Gastroenterol. 2016;111:78-86. [PMID: 26644276 DOI: 10.1038/ajg.2015.377] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 10.9] [Reference Citation Analysis]
72 Higuera-de-la-Tijera F, Servín-Caamaño AI, Salas-Gordillo F, Pérez-Hernández JL, Abdo-Francis JM, Camacho-Aguilera J, Alla SN, Jiménez-Ponce F. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. Can J Gastroenterol Hepatol 2018;2018:3015891. [PMID: 30079329 DOI: 10.1155/2018/3015891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
73 Felipo V. Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy. World J Gastroenterol 2006; 12(48): 7737-7743 [PMID: 17203513 DOI: 10.3748/wjg.v12.i48.7737] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
74 Merli M, Riggio O. Dietary and nutritional indications in hepatic encephalopathy. Metab Brain Dis 2009;24:211-21. [PMID: 19052853 DOI: 10.1007/s11011-008-9127-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
75 Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther. 2015;41:39-45. [PMID: 25339518 DOI: 10.1111/apt.12993] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
76 Shen YC, Chang YH, Fang CJ, Lin YS. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J 2019;18:34. [PMID: 31279342 DOI: 10.1186/s12937-019-0461-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
77 Wang QM, Ji Q, Duan ZJ, Zhang M, Chang QY. A study on the position and etiology of infection in cirrhotic patients: A potential precipitating factor contributing to hepatic encephalopathy. Exp Ther Med 2013;6:584-90. [PMID: 24137231 DOI: 10.3892/etm.2013.1137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
78 Gluud LL, Jeyaraj R, Morgan MY. Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:354-61. [PMID: 31360028 DOI: 10.1016/j.jceh.2019.02.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Ong JP, Oehler G, Krüger-jansen C, Lambert-baumann J, Younossi ZM. Oral L-Ornithine-L-Aspartate Improves Health-Related Quality of Life in Cirrhotic Patients with Hepatic Encephalopathy: An Open-Label, Prospective, Multicentre Observational Study. Clinical Drug Investigation 2011;31:213-20. [DOI: 10.2165/11586700-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
80 Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS One. 2016;11:e0146076. [PMID: 26745876 DOI: 10.1371/journal.pone.0146076] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
81 Ridola L, Nardelli S, Gioia S, Riggio O. Quality of life in patients with minimal hepatic encephalopathy. World J Gastroenterol 2018; 24(48): 5446-5453 [PMID: 30622374 DOI: 10.3748/wjg.v24.i48.5446] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
82 Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World J Hepatol 2015; 7(29): 2871-2879 [PMID: 26692331 DOI: 10.4254/wjh.v7.i29.2871] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
83 Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol 2015;5:S75-81. [PMID: 26041963 DOI: 10.1016/j.jceh.2014.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
84 Yang ZT, Chen HJ, Chen QF, Lin H. Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy.Front Neurol. 2018;9:14. [PMID: 29422882 DOI: 10.3389/fneur.2018.00014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
85 Yadav SK, Gupta RK, Saraswat VA, Rangan M, Thomas MA, Rutella S, Danese S, Wang E, Marincola FM, Haris M. Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology. J Transl Med 2015;13:322. [PMID: 26444271 DOI: 10.1186/s12967-015-0679-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Lin X, Huang X, Wang L, Feng S, Chen X, Cai W, Huang Z. Prognostic Value of Acute-On-Chronic Liver Failure (ACLF) Score in Critically Ill Patients with Cirrhosis and ACLF. Med Sci Monit 2020;26:e926574. [PMID: 32978936 DOI: 10.12659/MSM.926574] [Reference Citation Analysis]
87 Gairing SJ, Anders J, Kaps L, Nagel M, Michel M, Kremer WM, Hilscher M, Galle PR, Schattenberg JM, Wörns MA, Labenz C. Evaluation of IL-6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatol Commun 2022. [PMID: 35032100 DOI: 10.1002/hep4.1883] [Reference Citation Analysis]
88 Amodio P. The liver, the brain and nitrogen metabolism. Metab Brain Dis. 2009;24:1-4. [PMID: 19107584 DOI: 10.1007/s11011-008-9120-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Saab S. Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. Int J Gen Med. 2015;8:165-173. [PMID: 25999756 DOI: 10.2147/ijgm.s81878] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
90 Bai Z, Guo X, Tacke F, Li Y, Li H, Qi X. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization. Therap Adv Gastroenterol 2019;12:1756284819881302. [PMID: 31636711 DOI: 10.1177/1756284819881302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
91 Kumar R, Krishnamoorthy TL, Tan HK, Lui HF, Chow WC. Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure. Gastroenterol Rep (Oxf). 2015;3:122-127. [PMID: 25391261 DOI: 10.1093/gastro/gou075] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
92 Jin X, Chen D, Wu F, Zhang L, Huang Y, Lin Z, Wang X, Wang R, Xu L, Chen Y. Hydrogen Sulfide Protects Against Ammonia-Induced Neurotoxicity Through Activation of Nrf2/ARE Signaling in Astrocytic Model of Hepatic Encephalopathy. Front Cell Neurosci 2020;14:573422. [PMID: 33192318 DOI: 10.3389/fncel.2020.573422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
93 Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver. 2016;10:509-519. [PMID: 27377741 DOI: 10.5009/gnl15419] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
94 Kuan YC, Huang KW, Lin CL, Luo JC, Kao CH. Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis. J Clin Med 2019;8:E1108. [PMID: 31349746 DOI: 10.3390/jcm8081108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
95 Morega S, Cătălin B, Simionescu CE, Sapalidis K, Rogoveanu I. Cerebrolysin Prevents Brain Injury in a Mouse Model of Liver Damage. Brain Sciences 2021;11:1622. [DOI: 10.3390/brainsci11121622] [Reference Citation Analysis]
96 Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol 2015;13:2048-61. [PMID: 26164219 DOI: 10.1016/j.cgh.2015.06.039] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 12.4] [Reference Citation Analysis]
97 Adrover R, Cocozzella D, Ridruejo E, García A, Rome J, Podestá JJ. Breath-ammonia testing of healthy subjects and patients with cirrhosis. Dig Dis Sci. 2012;57:189-195. [PMID: 21842240 DOI: 10.1007/s10620-011-1858-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
98 Chen HJ, Shi HB, Jiang LF, Li L, Chen R. Disrupted topological organization of brain structural network associated with prior overt hepatic encephalopathy in cirrhotic patients. Eur Radiol 2018;28:85-95. [PMID: 28667481 DOI: 10.1007/s00330-017-4887-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
99 Blasco-Algora S, Masegosa-Ataz J, Gutiérrez-García ML, Alonso-López S, Fernández-Rodríguez CM. Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. World J Gastroenterol 2015; 21(42): 12125-12140 [PMID: 26576097 DOI: 10.3748/wjg.v21.i42.12125] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
100 Bale A, Pai CG, Shetty S, Balaraju G, Shetty A. Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. J Clin Exp Hepatol 2018;8:156-61. [PMID: 29892178 DOI: 10.1016/j.jceh.2017.06.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
101 Choudhary NS, Baijal SS, Saigal S, Agarwal A, Saraf N, Khandelwal R, Jain V, Khandelwal AH, Kapoor A, Jain D, Misra SR, Puri R, Sud R, Soin AS. Results of Portosystemic Shunt Embolization in Selected Patients with Cirrhosis and Recurrent Hepatic Encephalopathy. J Clin Exp Hepatol 2017;7:300-4. [PMID: 29234193 DOI: 10.1016/j.jceh.2017.03.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
102 Hillebrand DJ, Hill KB, Hu KQ, Strutt M, Wilson B, Cottrell A, Teichman S, Hay K, Bull B. Formal heparin anticoagulation protocol improves safety of charcoal-based liver-assist treatments. ASAIO J 2006;52:334-42. [PMID: 16760725 DOI: 10.1097/01.mat.0000206154.02253.9c] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Montagnese S, Amodio P, Morgan MY. Methods for Diagnosing Hepatic Encephalopathy in Patients with Cirrhosis: A Multidimensional Approach. Metab Brain Dis 2004;19:281-312. [DOI: 10.1023/b:mebr.0000043977.11113.2a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
104 Tapper EB, Patwardhan V, Mazer LM, Vaughn B, Piatkowski G, Evenson AR, Malik R. Predictors of negative intraoperative findings at emergent laparotomy in patients with cirrhosis. J Gastrointest Surg 2014;18:1777-83. [PMID: 25091839 DOI: 10.1007/s11605-014-2599-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14(23): 3609-3615 [PMID: 18595126 DOI: 10.3748/wjg.14.3609] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 87] [Article Influence: 7.0] [Reference Citation Analysis]
106 Hashimoto JG, Wiren KM, Wilhelm CJ. A neurotoxic alcohol exposure paradigm does not induce hepatic encephalopathy. Neurotoxicol Teratol 2016;56:35-40. [PMID: 27268733 DOI: 10.1016/j.ntt.2016.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
107 Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010;7:515-25. [DOI: 10.1038/nrgastro.2010.116] [Cited by in Crossref: 174] [Cited by in F6Publishing: 152] [Article Influence: 14.5] [Reference Citation Analysis]
108 Shen TC, Albenberg L, Bittinger K, Chehoud C, Chen YY, Judge CA, Chau L, Ni J, Sheng M, Lin A. Engineering the gut microbiota to treat hyperammonemia. J Clin Invest. 2015;125:2841-2850. [PMID: 26098218 DOI: 10.1172/jci79214] [Cited by in Crossref: 103] [Cited by in F6Publishing: 59] [Article Influence: 14.7] [Reference Citation Analysis]
109 Oey RC, Buck LEM, Erler NS, van Buuren HR, de Man RA. The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy. Therap Adv Gastroenterol 2019;12:1756284819858256. [PMID: 31258622 DOI: 10.1177/1756284819858256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
110 Elzubeir A, Alam SM. Letter to editor ‘prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with Rifaxamin’. World J Gastroenterol 2020; 26(44): 7085-7087 [PMID: 33311952 DOI: 10.3748/wjg.v26.i44.7085] [Reference Citation Analysis]
111 Bertot LC, Gomez EV, Almeida LA, Soler EA, Perez LB. Model for End-Stage Liver Disease and liver cirrhosis-related complications. Hepatol Int 2013;7:347-55. [PMID: 26201769 DOI: 10.1007/s12072-012-9403-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Maki H, Kaneko J, Arita J, Akamatsu N, Sakamoto Y, Hasegawa K, Tamura S, Takao H, Shibata E, Kokudo N. Proximal total splenic artery embolization for refractory hepatic encephalopathy. Clin J Gastroenterol 2018;11:156-60. [PMID: 29196972 DOI: 10.1007/s12328-017-0805-5] [Reference Citation Analysis]
113 Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc 2014;89:241-53. [PMID: 24411831 DOI: 10.1016/j.mayocp.2013.11.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
114 Oh SS, Kim YJ, Jang SI, Park S, Nam CM, Park EC. Hospitalizations and mortality among patients with fetal alcohol spectrum disorders: a prospective study. Sci Rep 2020;10:19512. [PMID: 33177533 DOI: 10.1038/s41598-020-76406-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
115 Dbouk N, McGuire BM. Hepatic encephalopathy: a review of its pathophysiology and treatment. Curr Treat Options Gastroenterol 2006;9:464-74. [PMID: 17081480 DOI: 10.1007/s11938-006-0003-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
116 Krishnarao A, Gordon FD. Prognosis of Hepatic Encephalopathy. Clin Liver Dis 2020;24:219-29. [PMID: 32245529 DOI: 10.1016/j.cld.2020.01.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, Tallis CJ, Stuart KA, Wright PL, Smith DD, Irvine KM, Powell EE, Cottrell WN. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World J Gastroenterol 2017; 23(40): 7321-7331 [PMID: 29142479 DOI: 10.3748/wjg.v23.i40.7321] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
118 Saad WE. Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy. Semin Intervent Radiol 2014;31:262-5. [PMID: 25177088 DOI: 10.1055/s-0034-1382795] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
119 Yousif MM, Sadek AMEM, Farrag HA, Selim FO, Hamed EF, Salama RI. Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. Intern Emerg Med 2019;14:753-61. [PMID: 30706253 DOI: 10.1007/s11739-019-02042-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
120 Pelle J, Castelli FA, Rudler M, Alioua I, Colsch B, Fenaille F, Junot C, Thabut D, Weiss N. Metabolomics in the understanding and management of hepatic encephalopathy. Anal Biochem 2022;636:114477. [PMID: 34808106 DOI: 10.1016/j.ab.2021.114477] [Reference Citation Analysis]
121 Ventura-Cots M, Carmona I, Moreno C, Ampuero J, Simón-Talero M, Sanpedro F, Les I, Romero-Gómez M, Genescà J. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therap Adv Gastroenterol 2018;11:1756283X17743419. [PMID: 29383024 DOI: 10.1177/1756283X17743419] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
122 Peck-Radosavljevic M, Angeli P, Cordoba J, Farges O, Valla D. Managing complications in cirrhotic patients. United European Gastroenterol J 2015;3:80-94. [PMID: 25653862 DOI: 10.1177/2050640614560452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
123 Zhu S, Waili Y, Qi X, Chen Y, Lou Y, Chen B. Serum C-reactive protein predicts early mortality in hospitalized patients with HBV-related decompensated cirrhosis. Medicine (Baltimore) 2017;96:e5988. [PMID: 28121954 DOI: 10.1097/MD.0000000000005988] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
124 Jara M, Dziodzio T, Malinowski M, Lüttgert K, Nikolov R, Ritschl PV, Öllinger R, Pratschke J, Stockmann M. Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis. Dig Dis Sci 2019;64:576-84. [PMID: 30406480 DOI: 10.1007/s10620-018-5360-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Ridola L, Faccioli J, Nardelli S, Gioia S, Riggio O. Hepatic Encephalopathy: Diagnosis and Management. J Transl Int Med 2020;8:210-9. [PMID: 33511048 DOI: 10.2478/jtim-2020-0034] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Ditisheim S, Giostra E, Burkhard PR, Goossens N, Mentha G, Hadengue A, Spahr L. A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis. BMC Gastroenterol 2011;11:134. [PMID: 22151412 DOI: 10.1186/1471-230X-11-134] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]